Yan Sun, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
4
3
2
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (4)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Jing Huang, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
Worked with same sponsors:
Shukui Qin, MD
NanJing PLA 81 Hospital
Shared therapeutic areas:
Worked with same sponsors:
Shukui Qin
NanJing PLA 81 Hospital
Shared therapeutic areas:
Worked with same sponsors:
Wenbin Shen, PhD
Hebei Medical University Fourth Hospital
Shared therapeutic areas:
Worked with same sponsors:
Vincent Chung
City of Hope Medical Center
Shared therapeutic areas:
Tsang-Wu Liu
Taiwan Cooperative Oncology Group, NHRI
Shared therapeutic areas:
Shuhang Wang
NCC, CICAMS
Shared therapeutic areas:
Worked with same sponsors:
Gao-jun Teng, M.D
Zhongda hospital, Southeast university, Nanjing, China
Shared therapeutic areas:
Worked with same sponsors:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Mark Jones, MD
Incyte Corporation
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (4)
Showing 4 of 4 trials
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
All 4 trials loaded